Intertek stock falls after board rejects EQT’s £58 takeover bid By Investing.com

Intertek rejected EQT’s revised £58.00 per share cash offer, saying it undervalues the company and carries execution risk; earlier £51.50 and £54.00 proposals were also turned down. The board is instead pursuing a strategic review of a potential separation of Intertek Energy & Infrastructure from Intertek Testing & Assurance, with completion targeted by mid-2027. Shares fell 3.2% Friday as the market digested the stalled takeover bid and separation plan.

Analysis

The market is treating this as a binary M&A event, but the more important signal is that management is effectively inviting a breakup premium and forcing EQT into a deadline-driven auction. That changes the negotiating geometry: once a sponsor is publicly rebuffed twice, the buyer’s ability to win on price alone weakens, and any final bid must now compensate for reputational damage and execution skepticism. The probability-weighted outcome is no longer just “deal or no deal,” but also a slower path to value realization through a separation process that could rerate the stock over months even without a transaction.

The hidden second-order effect is on asset quality dispersion. The higher-margin testing franchise should attract strategic buyers at a materially better multiple than the lower-margin energy/infrastructure unit, which means the separation could reveal that the sum of parts is worth more than the sponsor’s blended offer by a wide margin. That creates an optionality gap: if the sale process for the cyclical business disappoints, investors may still underwrite the stable division as a premium compounder, but if both pieces find separate buyers, the implied valuation could reset sharply higher.

Catalyst timing matters. The next two weeks are the acute event window for EQT’s response, but the real catalyst for holders is the mid-2027 separation roadmap, which gives management cover to keep the premium alive while they market assets sequentially. The tail risk is that the process drags and the market begins discounting time-to-cash, especially if macro softens and private equity capital becomes more selective on industrial assets with lower margins.

Consensus may be underestimating how much this situation compresses strategic alternatives across the quality assurance/testing space. If one asset-rich public company can signal willingness to split and sell, peers may face renewed scrutiny from activists or sponsors seeking similar disaggregation. The trade is not just about this name; it is about whether the market starts paying up for clean, high-ROIC testing exposures and punishing conglomerate structures with mediocre adjacent businesses.

Key Decisions for Investors

• Stay long ITRK into the May 14 deadline only as an event-driven trade; upside is driven by either a final EQT bump or a re-rating toward sum-of-parts, but size should be capped because failure to bid could see a 5-10% giveback.
• For investors who already own ITRK, monetize part of the event premium by selling upside calls 1-2 months out; this keeps exposure to a bid while reducing theta bleed if the process shifts into a slow strategic-review grind.
• Initiate a relative-value pair: long ITRK / short a lower-quality diversified industrial or inspection peer with weaker margins and less breakup optionality over the next 3-6 months; the thesis is that capital will reprice toward pure-play, high-margin testing assets.
• If EQT walks away, consider buying ITRK on the first post-event weakness for a 6-12 month hold; the separation narrative should remain a structural catalyst, and any sell-side modeling reset toward sum-of-parts could create another 10-15% upside leg.
• For sponsor-risk takers, avoid chasing EQT unless a materially improved bid emerges; the asymmetric risk is now to the downside if the process fails, with limited strategic value from a headline-driven, hard-to-close industrial asset.